Could it be time to talk in the long-running saga of Sanofi-Aventis' ($SNY) $18.5 billion bid for Genzyme ($GENZ)? CEOs Chris Viehbacher (photo) and Henri Termeer (photo) will have the chance when they give back-to-back presentation's at next week's JPMorgan Healthcare Conference. Report